FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) for Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia
On Jun. 4, 2020, Merck announced that the U.S. Food and Drug Administration (FDA) had approved a supplemental…